(Q38246130)

31 August 2017

title

Sirukumab : a novel therapy for lupus nephritis? (English)

1 reference

31 August 2017

Timothy B Niewold

2

0 references

author name string

Uma Thanarajasingam

series ordinal

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

5 September 2014

1 reference

Expert Opinion on Investigational Drugs

31 August 2017

published in

1 reference

31 August 2017

volume

23

1 reference

31 August 2017

issue

10

1 reference

31 August 2017

page(s)

1449-1455

1 reference

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Mortality in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Predictors of survival in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Rationale for interleukin-6 blockade in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Interleukin 6 promotes murine lupus in NZB/NZW F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Renal expression of IL-6 and TNFalpha genes in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Humanized antihuman IL-6 receptor antibody, tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Overview of safety of non-biologic and biologic DMARDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.950837

10.1517/13543784.2014.950837

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference